Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post FY2022 Earnings of ($9.22) Per Share, Jefferies Financial Group Forecasts
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post FY2022 Earnings of ($9.22) Per Share, Jefferies Financial Group Forecasts
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Research analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn ($9.22) per share for the year, up from their prior estimate of ($9.25). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share. Jefferies Financial Group also issued estimates for Ultragenyx Pharmaceutical's Q4 2022 earnings at ($2.25) EPS, Q1 2023 earnings at ($1.45) EPS, Q2 2023 earnings at ($1.41) EPS, Q3 2023 earnings at ($1.45) EPS, FY2023 earnings at ($5.64) EPS, FY2024 earnings at ($4.59) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at $0.35 EPS and FY2027 earnings at $12.32 EPS.
Ultragenyx制药公司(纳斯达克：Rare-Get Rating)-杰富瑞金融集团的研究分析师在2月1日星期三发布的一份研究报告中上调了对Ultragenyx制药公司2022财年每股收益的预期。杰富瑞金融集团(Jefferies Financial Group)分析师M.Raycroft现在预计，这家生物制药公司今年的每股收益将达到9.22美元，高于此前预测的9.25美元。对Ultragenyx制药公司目前全年收益的普遍估计是每股8.84美元。杰富瑞金融集团还发布了对Ultragenyx制药公司2022年第四季度每股收益(2.25美元)、2023年第一季度每股收益(1.45美元)、2023年第二季度每股收益(1.41美元)、2023年第三季度每股收益(1.45美元)、2023财年每股收益(5.64美元)、2024财年每股收益(4.59美元)、2025财年每股收益(5.19美元)、2026财年每股收益0.35美元和2027财年每股收益12.32美元的预期。
A number of other research analysts also recently issued reports on RARE. Cowen lowered their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Credit Suisse Group lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating on the stock in a report on Friday. SVB Leerink lowered their price target on Ultragenyx Pharmaceutical from $115.00 to $108.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $82.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, December 30th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $91.69.
其他一些研究分析师最近也发布了关于REARE的报告。考恩在11月3日星期四的一份报告中将他们对Ultragenyx制药公司的目标价从86.00美元下调至65.00美元。瑞士信贷集团在11月3日周四的一份报告中将Ultragenyx Pharmtics的目标价从105.00美元下调至96美元，并对该股设定了“跑赢大盘”的评级。摩根士丹利在周五的一份报告中将他们对Ultragenyx Pharmtics的目标价从100.00美元下调至95美元，并对该股设定了“增持”评级。SVB Leerink在11月3日周四的一份报告中将他们对Ultragenyx Pharmtics的目标价从115.00美元下调至108.00美元，并对该股设定了“跑赢大盘”的评级。最后，在12月30日星期五的一份报告中，HC Wainwright重申了买入评级，并为Ultragenyx制药公司的股票设定了82.00美元的目标价。三位分析师对该股的评级为持有，十位分析师对该公司的评级为买入。根据MarketBeat.com的数据，该公司的普遍评级为“适度买入”，平均目标价为91.69美元。
Ultragenyx Pharmaceutical Trading Down 3.4 %
Ultragenyx制药公司股价下跌3.4%
Institutional Trading of Ultragenyx Pharmaceutical
Ultragenyx制药公司的制度性交易
Several institutional investors have recently made changes to their positions in RARE. RTW Investments LP grew its position in shares of Ultragenyx Pharmaceutical by 71.9% during the third quarter. RTW Investments LP now owns 2,359,996 shares of the biopharmaceutical company's stock worth $97,727,000 after purchasing an additional 986,712 shares in the last quarter. State Street Corp grew its holdings in Ultragenyx Pharmaceutical by 26.1% during the 2nd quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company's stock valued at $146,603,000 after buying an additional 508,624 shares in the last quarter. Wellington Management Group LLP grew its holdings in Ultragenyx Pharmaceutical by 17.1% during the 1st quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company's stock valued at $244,747,000 after buying an additional 492,842 shares in the last quarter. BlackRock Inc. grew its holdings in Ultragenyx Pharmaceutical by 9.2% during the 3rd quarter. BlackRock Inc. now owns 3,927,639 shares of the biopharmaceutical company's stock valued at $162,645,000 after buying an additional 330,055 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $12,663,000. Hedge funds and other institutional investors own 93.17% of the company's stock.
几家机构投资者最近改变了他们在Rare的头寸。RTW Investments LP在第三季度将其在Ultragenyx制药公司的股票头寸增加了71.9%。RTW Investments LP现在拥有这家生物制药公司2,359,996股票，价值97,727,000美元，上个季度又购买了986,712股票。道富集团在第二季度增持了26.1%的Ultragenyx Pharmtics股份。道富集团目前持有这家生物制药公司2,457,308股股票，价值146,603,000美元，上一季度又购买了508,624股。惠灵顿管理集团有限责任公司在第一季度增持了17.1%的Ultragenyx制药股份。惠灵顿管理集团(Wellington Management Group LLP)现在拥有这家生物制药公司3370,245股股票，价值244,747,000美元，上个季度又购买了492,842股。贝莱德股份有限公司在第三季度增持了Ultragenyx制药9.2%的股份。贝莱德股份有限公司现在持有这家生物制药公司3,927,639股股票，价值162,645,000美元，上个季度又购买了330,055股。最后，Evende Asset Management LLC在第三季度购买了Ultragenyx制药公司的一个新头寸，价值约为12,663,000美元。对冲基金和其他机构投资者持有该公司93.17%的股票。
Insider Transactions at Ultragenyx Pharmaceutical
Ultragenyx制药公司的内幕交易
In other news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm's stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the transaction, the chief accounting officer now owns 16,197 shares of the company's stock, valued at $712,020.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.70% of the company's stock.
在其他新闻方面，首席财务官西奥多·艾伦·惠曾加在12月21日星期三的一笔交易中出售了2031股该公司的股票。这只股票的平均售价为43.96美元，总价值为89,282.76美元。交易完成后，这位首席会计官现在持有该公司16,197股股票，价值712,020.12美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过这个环节。公司内部人士持有该公司6.70%的股份。
Ultragenyx Pharmaceutical Company Profile
Ultragenyx制药公司简介
(Get Rating)
(获取评级)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Ultragenyx制药公司是一家生物制药公司，从事治疗严重罕见和超罕见遗传病的新产品的识别、收购、开发和商业化。其产品包括Mepsevii和Crysvita。Mepsevii是一种静脉酶替代疗法，用于治疗粘多糖病VII。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免费获取StockNews.com关于Ultragenyx制药公司的研究报告(Rare)
- 市场回顾周-1/30-2/3
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Ultragenyx药学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ultragenyx制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。